Neurosense finalizing protocol for Phase 3 trial of PrimeC for ALS
Neurosense Therapeutics is working on finishing touches for the protocol of a Phase 3 study testing PrimeC, an oral…
Articles by Margarida Maia, PhD
Medicare Advantage plans in US told to cover Qalsody for SOD1-ALS
The Centers for Medicare and Medicaid Services (CMS) has issued a directive requiring that Medicare Advantage plans cover Qalsody…
Study finds early-life events may be environmental risk factors for ALS
People with amyotrophic lateral sclerosis (ALS) are more likely than those without the neurodegenerative disease to have grown up…
MN-166 may slow ALS progression over year, trial data suggest
MN-166 (ibudilast), an investigational oral treatment for amyotrophic lateral sclerosis (ALS), appears to slow disease progression over up…
Utreloxastat fails to slow ALS disease progression in Phase 2 trial
Twice-daily treatment with PTC Therapeutics’ oral candidate utreloxastat failed to significantly slow disease progression in adults with amyotrophic…
Lilly to develop ALS therapies against targets ID’d with Verge tech
Eli Lilly will develop therapies against two drug targets for amyotrophic lateral sclerosis (ALS) that were identified and…
First-in-human trial of ALS therapy ASHA-624 expected in early 2025
A newly awarded grant from the ALS Association will support Asha Therapeutics‘ work to advance ASHA-624, a small…
Mitochondrial genome mutations linked to ALS in genetic study
Mutations in the mitochondrial genome — the set of DNA instructions found inside mitochondria, the powerhouses of cells — may…
EMA’s CHMP upholds its negative opinion on masitinib for ALS
An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB…
First SOD1-ALS patient dosed in trial of AMT-162 gene therapy
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development…